Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

The Canadian Standards Association Technical Committee Z252.11 for Lab-developed Tests provides information

Edward Dunn and Robert Rennie
CMAJ October 05, 2020 192 (40) E1166-E1167; DOI: https://doi.org/10.1503/cmaj.76509
Edward Dunn
Director, Product and service development, Dynacare, Brampton, Ont.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Rennie
Provincial microbiology consultant, RP Rennie Consultations Ltd.; Professor emeritus, Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In response to the 2019 CMAJ commentary by Holloway and colleagues,1 we wish to clarify:

  • the role of the Canadian Standards Association (CSA) in standards development;

  • the link between voluntary standards and laboratory accreditation requirements; and

  • the financial and in-kind support received for the development of the CSA standard referenced in the commentary.

The CSA (operating as “CSA Group”) is a private, not-for-profit company that publishes voluntary standards and related documents through a consensus-based standards development process approved by the Standards Council of Canada. This process brings together volunteers who represent varied viewpoints and interests to achieve consensus.

The first edition of CSA Z316.8:18 requirements for the design, development and validation of laboratory-developed tests used for the screening, diagnosis and management of clinical conditions assists in achieving harmonization of the management of laboratory-developed tests. The standard provides guidance to laboratories and assists accreditation bodies in the establishment of a standardized validation process.

The standard provides a distinction between testing done in a research setting versus in a clinical setting. A laboratory-developed test is intended to assist in clinical diagnosis or to be used in making decisions concerning clinical management. This test is a type of in vitro diagnostic test that is designed, created, validated and used within a single laboratory. Laboratory-developed tests can be shared by paternal laboratory networks (including technology transfer from provincial/territorial, federal and private laboratories), which are frequently involved in the maintenance of test-performance features. However, the ultimate test performance is the responsibility of a single laboratory. Tests clearly labelled and marketed for research use only by the manufacturer may be used in a clinical setting for diagnosis or managing treatment only if they are technically and clinically validated within the laboratory carrying out the testing. Once validated for clinical use, a test labelled as research use only is considered a laboratory-devloped test and can be used in the clinical laboratory. The standard does not apply to tests that are developed by a laboratory for research purposes until such time that the test becomes applied to clinical testing and has undergone suitable validation according to the requirements in the CSA standard.

Laboratories validate laboratory-developed tests by establishing acceptable test-performance requirements through analytical and clinical testing. Laboratories then reverify performance as part of implementation, including precision, accuracy, bias, limit of detection, linearity, selectivity, analytical specificity, stability, dilution effects, carryover, reference/therapeutic range and clinical validation. The measuring and reference intervals should be determined. A validation summary should be written by the laboratory to summarize experiments and determine acceptance criteria, equivalent to the package insert for a commercial approved test.

A voluntary standard, such as those produced by CSA Group, can be referenced by an accreditation body, which may choose to mandate the standard in its entirety or certain clauses to assess laboratory compliance with the standard. For instance, the Institute for Quality Management in Healthcare accreditation body incorporated the CSA Z316.8:18 standard into its accreditation requirements in December 2019, which took effect for all accreditation assessments as of Jan. 1, 2020. The institute program is mandatory in 3 Canadian provinces: Ontario, New Brunswick and Newfoundland and Labrador. The CSA Z316.8:18 standard is also being implemented by the College of Physicians and Surgeons of Alberta via the Western Canada Diagnostic Accreditation Alliance.

Members of CSA technical committees and subcommittees provide technical expertise in the content development of standards; they do not act on behalf of the association or organization where they are employed. Financial support to develop the standard was provided, in part, from the governments of the provinces and territories, as administered by the Canadian Agency for Drugs and Technologies in Health, Canadian Society for Medical Laboratory Science, Alere ULC, Siemens and Roche, and developed in accordance with CSA Group’s accredited process. The standard was developed by voluntary members of the technical subcommittee for laboratory-developed tests and approved by the technical committee. Members represent their respective stakeholder groups and are chosen based on their experience relevant to these groups.

The technical subcommittee accounted for the needs of regulatory authorities, consumers, contractors, providers of related services and other users when developing the technical content of the standard. The standard was developed in such a way that it could be adopted by regulators and to lay the groundwork for potential future development. When the requirements in the standard were developed, the technical subcommittee determined the best technical resolution to provide the minimum guidelines that any affected stakeholder could implement to ensure best safety practices. At the time of development, this standard was intended to provide a basis for the implementation of a consistent laboratory-developed testing development process across Canada. The technical subcommittee is currently reviewing the potential for additional standard development in the genetic topic area.

Problematic laboratory-developed tests in the onset of the coronavirus disease 2019 pandemic are the result of fast response for the emergent medical need. The referenced example is a Centers for Disease Control and Prevention qPCR-based test design for severe acute respiratory syndrome coronavirus 2 acute infection (www.sciencemag.org/news/2020/02/united-states-badly-bungled-coronavirus-testing-things-may-soon-improve). This was corrected within a few days thanks to the decentralized and parallel modality laboratory-developed tests that were produced and transparently compared in real time among laboratory professionals. This offers the best mode to reach international consensus in performance in the current pandemic situation. Health Canada regulates in vitro diagnostic tests; a manufacturer has to apply for approval before being allowed to market and sell the test kits or reagents in Canada.

Health Canada’s jurisdiction does not extend to tests developed within Canadian clinical laboratories that are not intended for sale or distribution to other laboratories. Regulation at this level rests with each provincial health ministry, and each province has its own system for regulation of clinical laboratories. The necessary oversight of laboratory-developed tests by accreditation of laboratories varies according to provincial accreditation programs’ requirements.

At the time of development, this standard was intended to provide a basis for the implementation of a consistent development process for laboratory-developed testing across Canada. It provides guidance to both the laboratories developing tests for use in their own laboratories, as well as for accreditation bodies.

Footnotes

  • Competing interests: None declared.

Reference

  1. ↵
    1. Holloway K,
    2. Miller FA,
    3. Rousseau F,
    4. et al
    . Health Canada needs to act on laboratory-developed diagnostics. CMAJ 2019;191:E1067–9.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (40)
CMAJ
Vol. 192, Issue 40
5 Oct 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Canadian Standards Association Technical Committee Z252.11 for Lab-developed Tests provides information
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Canadian Standards Association Technical Committee Z252.11 for Lab-developed Tests provides information
Edward Dunn, Robert Rennie
CMAJ Oct 2020, 192 (40) E1166-E1167; DOI: 10.1503/cmaj.76509

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The Canadian Standards Association Technical Committee Z252.11 for Lab-developed Tests provides information
Edward Dunn, Robert Rennie
CMAJ Oct 2020, 192 (40) E1166-E1167; DOI: 10.1503/cmaj.76509
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • Reference
  • Responses
  • Metrics
  • PDF

Related Articles

  • Health Canada needs to act on laboratory-developed diagnostics
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire